Diabetes and Weight-Loss Drugs Show Promise in Reducing Addiction Risk
A class of medications widely used to treat diabetes and obesity may also hold promise in reducing the risk of addiction and helping people already struggling with substance dependence, according to emerging research.
Drugs such as Semaglutide, marketed under brand names including Ozempic and Wegovy, as well as Liraglutide and Tirzepatide, belong to a class of medicines known as glucagon-like peptide-1 (GLP-1) receptor agonists. Originally developed to control blood sugar in people with Type 2 Diabetes and later approved for weight management, scientists now believe these drugs may influence brain pathways linked to cravings and addictive behaviour.
GLP-1 receptor agonists mimic a naturally occurring hormone that helps regulate blood sugar levels and appetite. By slowing digestion and promoting a feeling of fullness, they reduce food intake and assist with weight loss. However, researchers have increasingly noticed that the drugs appear to affect areas of the brain involved in reward and impulse control.
Early findings suggest the medications may dampen the brain’s response to substances that typically trigger addictive behaviour. This includes alcohol, nicotine and certain drugs that stimulate the brain’s reward system. Scientists say the mechanism may involve the regulation of dopamine signalling in the brain, which plays a crucial role in reinforcing pleasurable experiences and cravings.
In recent clinical and observational studies, patients taking GLP-1 medications for diabetes or obesity reported reduced urges to drink alcohol, smoke cigarettes or engage in other compulsive behaviours. Some individuals with a history of addiction also appeared less likely to relapse while on the treatment.
Researchers caution that the findings are still preliminary, and more rigorous clinical trials are required before the drugs can be prescribed specifically for addiction treatment. Nevertheless, the results are generating growing interest among addiction specialists who have long struggled to find effective medications for many forms of substance dependence.
Addiction remains one of the most difficult public health challenges worldwide. Conditions such as Alcohol Use Disorder and Opioid Use Disorder affect millions of people, yet available treatments are limited and relapse rates remain high.
If further research confirms the benefits, GLP-1 receptor agonists could open a new frontier in addiction medicine by targeting the biological drivers of cravings rather than relying solely on behavioural therapy or substitute medications.
Scientists say the possibility that drugs already widely used for metabolic conditions could also treat addictive disorders offers a potentially faster path to new therapies. Because these medications have already undergone extensive safety testing for diabetes and obesity, researchers believe it may be easier to adapt them for addiction treatment than developing entirely new drugs.
For now, experts urge caution while the science evolves. But the growing body of evidence suggests that medicines originally designed to control blood sugar and appetite may ultimately play a role in addressing one of society’s most persistent and devastating health problems.
Photograph: George Frey/Reuters